{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:01:53Z","timestamp":1793638913007,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000200","name":"united states agency for international development","doi-asserted-by":"publisher","award":["RFA-656-16-00004"],"award-info":[{"award-number":["RFA-656-16-00004"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Due to the threat of emerging anti-malarial resistance, the World Health Organization recommends incorporating surveillance for molecular markers of anti-malarial resistance into routine therapeutic efficacy studies (TESs). In 2018, a TES of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) was conducted in Mozambique, and the prevalence of polymorphisms in the <jats:italic>pfk13<\/jats:italic>, <jats:italic>pfcrt,<\/jats:italic> and <jats:italic>pfmdr1<\/jats:italic> genes associated with drug resistance was investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Children aged 6\u201359\u00a0months were enrolled in four study sites. Blood was collected and dried on filter paper from participants who developed fever within 28\u00a0days of initial malaria treatment. All samples were first screened for <jats:italic>Plasmodium falciparum<\/jats:italic> using a multiplex real-time PCR assay, and polymorphisms in the <jats:italic>pfk13<\/jats:italic>, <jats:italic>pfcrt,<\/jats:italic> and <jats:italic>pfmdr1<\/jats:italic> genes were investigated by Sanger sequencing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No <jats:italic>pfk13<\/jats:italic> mutations, associated with artemisinin partial resistance, were observed. The only <jats:italic>pfcrt<\/jats:italic> haplotype observed was the wild type CVMNK (codons 72\u201376), associated with chloroquine sensitivity. Polymorphisms in <jats:italic>pfmdr1<\/jats:italic> were only observed at codon 184, with the mutant 184F in 43\/109 (39.4%) of the samples, wild type Y184 in 42\/109 (38.5%), and mixed 184F\/Y in 24\/109 (22.0%). All samples possessed N86 and D1246 at these two codons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In 2018, no markers of artemisinin resistance were documented. Molecular surveillance should continue to monitor the prevalence of these markers to inform decisions on malaria treatment in Mozambique.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-021-03930-9","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T22:08:29Z","timestamp":1634076509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018"],"prefix":"10.1186","volume":"20","author":[{"given":"Arlindo","family":"Chidimatembue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaly S.","family":"Svigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"A\u00edde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Nhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00eddia","family":"Nhamussua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e9nio","family":"Nhacolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quique","family":"Bassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Criz\u00f3lgo","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f3nia","family":"Enosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abuchahama","family":"Saifodine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"De Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baltazar","family":"Candrinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Zulliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatachalam","family":"Udhayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi W.","family":"Lucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Halsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eus\u00e9bio","family":"Macete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"3930_CR1","unstructured":"WHO. World malaria report 2020: 20 years of global progress and challenges. Geneva, World Health Organization. 2020. https:\/\/apps.who.int\/iris\/handle\/10665\/337660. Accessed May 2021."},{"key":"3930_CR2","unstructured":"National Malaria Control Programme (NMCP). 2017\u20132022 National malaria control strategic plan. Mozambique. 2017. http:\/\/pdf.usaid.gov. Accessed May 2021."},{"key":"3930_CR3","unstructured":"President\u2019s Malaria Initiative (PMI). Evaluation of the impact of malaria control interventions on all-cause mortality in children under five years of age in Mozambique\u2014Mozambique Malaria Impact Evaluation Group. 2016; p. 155. http:\/\/pdf.usaid.gov. Accessed May 2021."},{"key":"3930_CR4","unstructured":"WHO. Guidelines for malaria. Geneva, World Health Organization. 2021. https:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria. Accessed May 2021."},{"key":"3930_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1046\/j.1365-3156.2003.01182.x","volume":"9","author":"F Abacassamo","year":"2004","unstructured":"Abacassamo F, Enosse S, Aponte JJ, G\u00f3mez-Oliv\u00e9 FX, Quint\u00f3 L, Mabunda S, et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health. 2004;9:200\u20138.","journal-title":"Trop Med Int Health"},{"key":"3930_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/1475-2875-13-309","volume":"13","author":"A Nhama","year":"2014","unstructured":"Nhama A, Bassat Q, Enosse S, Nhacolo A, Mutemba R, Carvalho E, et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. Malar J. 2014;13:309.","journal-title":"Malar J"},{"key":"3930_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.actatropica.2017.03.032","volume":"171","author":"C Salvador","year":"2017","unstructured":"Salvador C, Rafael B, Matsinhe F, Candrinho B, Muthemba R, De Carvalho E, et al. Efficacy and safety of artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015. Acta Trop. 2017;171:146\u201350.","journal-title":"Acta Trop"},{"key":"3930_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/1475-2875-13-300","volume":"13","author":"E Lobo","year":"2014","unstructured":"Lobo E, De Sousa B, Rosa S, Figueiredo P, Lobo L, Pateira S, et al. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance\/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malar J. 2014;13:300.","journal-title":"Malar J"},{"key":"3930_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1051\/parasite\/2018021","volume":"25","author":"M Ouji","year":"2018","unstructured":"Ouji M, Augereau JM, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.","journal-title":"Parasite"},{"key":"3930_CR10","first-page":"23","volume":"505","author":"F Ariey","year":"2016","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Ma L, Lim P, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2016;505:23\u201330.","journal-title":"Nature"},{"key":"3930_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0140-6736(12)60484-X","volume":"379","author":"AP Phyo","year":"2012","unstructured":"Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960\u20136.","journal-title":"Lancet"},{"key":"3930_CR12","first-page":"139","volume":"176","author":"C Amaratunga","year":"2017","unstructured":"Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin\u2013piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2017;176:139\u201348.","journal-title":"Lancet Infect Dis"},{"key":"3930_CR13","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"3930_CR14","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response 10 years of surveillance (2010\u20132019). Geneva, World Health Organization. 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240012813. Accessed May 2021."},{"key":"3930_CR15","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"3930_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3201\/eid2701.203527","volume":"27","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, Van LW, Habarugira F, Tacoli C, J\u00e4ger JC, Savelsberg D, et al. Increase in kelch 13 polymorphisms in Plasmodium falciparum, Southern Rwanda. Emerg Infect Dis. 2021;27:5\u20137.","journal-title":"Emerg Infect Dis"},{"key":"3930_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3201\/eid2401.170864","volume":"24","author":"H Gupta","year":"2018","unstructured":"Gupta H, Macete E, Bulo H, Salvador C, Warsame M, Carvalho E, et al. Drug-resistant polymorphisms and copy numbers in Plasmodium falciparum, Mozambique, 2015. Emerg Infect Dis. 2018;24:40\u20138.","journal-title":"Emerg Infect Dis"},{"key":"3930_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240174","volume":"15","author":"H Gupta","year":"2020","unstructured":"Gupta H, Galatas B, Chidimatembue A, Huijben S, Cister\u00f3 P, Matambisso G, et al. Effect of mass dihydroartemisinin\u2013piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance. PLoS ONE. 2020;15: e0240174.","journal-title":"PLoS ONE"},{"key":"3930_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.meegid.2005.09.001","volume":"6","author":"G Holmgren","year":"2006","unstructured":"Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bj\u00f6rkman A. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol. 2006;6:309\u201314.","journal-title":"Infect Genet Evol"},{"key":"3930_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4269\/ajtmh.2006.75.155","volume":"75","author":"CT Happi","year":"2006","unstructured":"Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, et al. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg. 2006;75:155\u201361.","journal-title":"Am J Trop Med Hyg"},{"key":"3930_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM200101253440403","volume":"344","author":"A Djimd\u00e9","year":"2001","unstructured":"Djimd\u00e9 A, Doumbo O, Cortese J, Kayentao K, Doumbo S, Diourt\u00e9 Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257\u201363.","journal-title":"N Engl J Med"},{"key":"3930_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.4269\/ajtmh.12-0525","volume":"88","author":"TT Thomsen","year":"2013","unstructured":"Thomsen TT, Madsen LB, Hansson HH, Tom\u00e1s EVE, Charlwood D, Bygbjerg IC, et al. Rapid selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique. Am J Trop Med Hyg. 2013;88:536\u201341.","journal-title":"Am J Trop Med Hyg"},{"key":"3930_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12936-015-0642-2","volume":"14","author":"NB Gadalla","year":"2015","unstructured":"Gadalla NB, Tavera G, Mu J, Kabyemela ER, Fried M, Duffy PE, et al. Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy. Malar J. 2015;14:129.","journal-title":"Malar J"},{"key":"3930_CR24","first-page":"293","volume":"221","author":"S Huijben","year":"2020","unstructured":"Huijben S, Macete E, Mombo-Ngoma G, Ramharter M, Kariuki S, Desai M, et al. Counter-selection of antimalarial resistance polymorphisms by intermittent preventive treatment in pregnancy. J Infect Dis. 2020;221:293\u2013303.","journal-title":"J Infect Dis"},{"key":"3930_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","volume":"91","author":"M Venkatesan","year":"2014","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833\u201343.","journal-title":"Am J Trop Med Hyg"},{"key":"3930_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12936-017-1868-y","volume":"16","author":"CN Nguetse","year":"2017","unstructured":"Nguetse CN, Adegnika AA, Agbenyega T, Ogutu BR, Krishna S, Kremsner PG, et al. Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria. Malar J. 2017;16:217.","journal-title":"Malar J"},{"key":"3930_CR27","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, World Health Organization. 2009. https:\/\/www.who.int\/docs\/default-source\/documents\/publications\/gmp\/methods-for-surveillance-of-antimalarial-drug-efficacy.pdf?sfvrsn=29076702_2. Accessed May 2021."},{"key":"3930_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3201\/eid2313.170366","volume":"23","author":"ES Halsey","year":"2017","unstructured":"Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity development through the US President\u2019s malaria initiative-supported antimalarial resistance monitoring in Africa network. Emerg Infect Dis. 2017;23:53\u20136.","journal-title":"Emerg Infect Dis"},{"key":"3930_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056677","volume":"8","author":"NW Lucchi","year":"2013","unstructured":"Lucchi NW, Narayanan J, Karell MA, Xayavong M, Kariuki S, DaSilva AJ, et al. Molecular diagnosis of malaria by photo-induced electron transfer fluorogenic primers: PET-PCR. PLoS ONE. 2013;8: e56677.","journal-title":"PLoS ONE"},{"key":"3930_CR30","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1086\/651949","volume":"201","author":"S Vinayak","year":"2010","unstructured":"Vinayak S, Alam T, Sem R, Shah N, Susanti A, Lim P, et al. Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia. J Infect Dis. 2010;201:1551\u201360.","journal-title":"J Infect Dis"},{"key":"3930_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136099","volume":"10","author":"E Talundzic","year":"2015","unstructured":"Talundzic E, Chenet SM, Goldman IF, Patel DS, Nelson JA, Plucinski MM, et al. Genetic analysis and species specific amplification of the artemisinin resistance-associated kelch propeller domain in P. falciparum and P. vivax. PLoS ONE. 2015;10: e0136099.","journal-title":"PLoS ONE"},{"key":"3930_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119215","volume":"10","author":"C Escobar","year":"2015","unstructured":"Escobar C, Pateira S, Lobo E, Lobo L, Teodosio R, Dias F, et al. Polymorphisms in Plasmodium falciparum K13-propeller in angola and mozambique after the introduction of the ACTs. PLoS ONE. 2015;10: e0119215.","journal-title":"PLoS ONE"},{"key":"3930_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1051\/parasite\/2016069","volume":"23","author":"AF Som\u00e9","year":"2016","unstructured":"Som\u00e9 AF, Sorgho H, Zongo I, Bazi\u00e9 T, Niki\u00e9ma F, Sawadogo A, et al. Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite. 2016;23:60.","journal-title":"Parasite"},{"key":"3930_CR34","doi-asserted-by":"publisher","first-page":"e00802","DOI":"10.1128\/AAC.00802-19","volume":"63","author":"SA Matrevi","year":"2019","unstructured":"Matrevi SA, Opoku-Agyeman P, Quashie NB, Bruku S, Abuaku B, Koram KA, et al. Plasmodium falciparum kelch propeller polymorphisms in clinical isolates from Ghana from 2007 to 2016. Antimicrob Agents Chemother. 2019;63:e00802-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"3930_CR35","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/s41598-017-01365-4","volume":"7","author":"B Galatas","year":"2017","unstructured":"Galatas B, Nhamussua L, Candrinho B, Mabote L, Cister\u00f3 P, Gupta H, et al. In-vivo efficacy of chloroquine to clear asymptomatic infections in Mozambican adults: a randomized, placebo-controlled trial with implications for elimination strategies. Sci Rep. 2017;7:1356.","journal-title":"Sci Rep"},{"key":"3930_CR36","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1038\/s41598-020-60549-7","volume":"10","author":"GM Bwire","year":"2020","unstructured":"Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AAR. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Sci Rep. 2020;10:3500.","journal-title":"Sci Rep"},{"key":"3930_CR37","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12936-016-1637-3","volume":"15","author":"S Mwanza","year":"2016","unstructured":"Mwanza S, Joshi S, Nambozi M, Chileshe J, Malunga P, Kabuya JBB, et al. The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. Malar J. 2016;15:584.","journal-title":"Malar J"},{"key":"3930_CR38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/infdis\/jiu216","volume":"210","author":"AEP Frosch","year":"2014","unstructured":"Frosch AEP, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, et al. Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis. 2014;210:1110\u20134.","journal-title":"J Infect Dis"},{"key":"3930_CR39","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1086\/596738","volume":"199","author":"C Sisowath","year":"2009","unstructured":"Sisowath C, Petersen I, Veiga MI, M\u00e5rtensson A, Premji Z, Bj\u00f6rkma A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199:750\u20137.","journal-title":"J Infect Dis"},{"key":"3930_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000999","volume":"3","author":"LC Okell","year":"2018","unstructured":"Okell LC, Reiter LM, Ebbe LS, Baraka V, Bisanzio D, Watson OJ, et al. Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether\u2013lumefantrine and artesunate\u2013amodiaquine in Africa. BMJ Glob Health. 2018;3: e000999.","journal-title":"BMJ Glob Health"},{"key":"3930_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.","journal-title":"Malar J"},{"key":"3930_CR42","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/infdis\/jir486","volume":"204","author":"FN Baliraine","year":"2011","unstructured":"Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis. 2011;204:1120\u20134.","journal-title":"J Infect Dis"},{"key":"3930_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijpddr.2014.07.003","volume":"4","author":"J Okombo","year":"2014","unstructured":"Okombo J, Kamau AW, Marsh K, Sutherland CJ, Ochola-Oyier LI. Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. Int J Parasitol Drugs Drug Resist. 2014;4:152\u201363.","journal-title":"Int J Parasitol Drugs Drug Resist"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03930-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03930-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03930-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T22:13:42Z","timestamp":1634076822000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03930-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3930"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03930-9","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"18 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the National Bioethics Committee for Health of Mozambique (CNBS\u2014IRB00002657) on December 13, 2017, (Ref. 516\/CNBS\/17). The Office of the Associate Director for Science in the Center for Global Health at Centers for Disease Control and Prevention (CDC) determined the work to be a non-engaged research activity without requirement for CDC IRB review (Ref. 2017-361).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"398"}}